HDAC Inhibitors As Novel Targeted Therapies for NUP98-HOXA9 AML Patients

被引：1
|
作者：
Rio-Machin, Ana [1 ,2 ]
Gomez-Lopez, Gonzalo [3 ]
Maiques-Diaz, Alba [2 ]
Alvarez, Sara [2 ]
Calasanz, Maria Jose [4 ]
Fitzgibbon, Jude [1 ]
Cigudosa, Juan C. [2 ]
机构：
[1] Queen Mary Univ London, Barts Canc Inst, Ctr Haematooncol, London, England
[2] Ctr Nacl Invest Oncol, Mol Cytogenet Grp, Human Canc Genet Programme, Madrid, Spain
[3] Ctr Nacl Invest Oncol, Bioinformat Unit, Madrid, Spain
[4] Univ Navarra, Sch Med, Dept Genet, IDISNA, Pamplona, Spain
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.2685.2685
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2685
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Faggot cells in acute myeloid leukemia with t(7;11)(p15;p15) and NUP98-HOXA9 fusion
    Hiroto Yanagisawa
    Shuichi Mizuta
    Hiroshi Kawabata
    Shino Fujimoto
    Tomoyuki Sakai
    Haruka Iwao-Kawanami
    Takafumi Kawanami
    Kazunori Yamada
    Toshihiro Fukushima
    Katsunori Kyoda
    Yasufumi Masaki
    Annals of Hematology, 2021, 100 : 2121 - 2123
  • [42] NUP98-HOXA9 drives High-Risk Myeloid Disease in Zebrafish - An In Vivo platform to Study Interacting Genes and Perform Drug Discovery
    Forrester, A. Michael
    Coombs, Andrew J.
    McBride, Eileen R.
    Chute, Ian
    Leger, Daniel
    Lewis, Stephen
    Grabher, Clemens
    Look, Thomas
    Berman, Jason N.
    BLOOD, 2011, 118 (21) : 1547 - 1547
  • [43] Faggot cells in acute myeloid leukemia with t(7;11)(p15;p15) and NUP98-HOXA9 fusion
    Yanagisawa, Hiroto
    Mizuta, Shuichi
    Kawabata, Hiroshi
    Fujimoto, Shino
    Sakai, Tomoyuki
    Iwao-Kawanami, Haruka
    Kawanami, Takafumi
    Yamada, Kazunori
    Fukushima, Toshihiro
    Kyoda, Katsunori
    Masaki, Yasufumi
    ANNALS OF HEMATOLOGY, 2021, 100 (08) : 2121 - 2123
  • [44] NUP98-HOXA9融合基因阳性的急性髓系白血病1例并文献复习
    朱海霞
    杨威
    中国实用内科杂志, 2014, 34 (11) : 1124 - 1125
  • [45] NUP98-HOXA9融合基因转基因小鼠的建立及乙烷亚硝基脲诱变的研究
    陆顺元
    顾鸣敏
    王阳
    谭轶
    孙岳平
    王龙
    孔辉
    陆振虞
    王铸钢
    中华血液学杂志, 2004, (05) : 4 - 8
  • [46] Additional acquisition of t(1;21)(p32;q22) in a patient relapsing with acute myelogenous leukemia with NUP98-HOXA9
    Takatoshi Aoki
    Toshihiro Miyamoto
    Shuro Yoshida
    Asataro Yamamoto
    Takuji Yamauchi
    Goichi Yoshimoto
    Yasuo Mori
    Kenjiro Kamezaki
    Hiromi Iwasaki
    Katsuto Takenaka
    Naoki Harada
    Koji Nagafuji
    Takanori Teshima
    Koichi Akashi
    International Journal of Hematology, 2008, 88 : 571 - 574
  • [47] Enforced expression of Nup98-HOXA9 in human CD34+cells provides a proliferative advantage and enhances stem cell self renewal.
    Chung, KY
    Morrone, G
    Schuringa, JJ
    Shieh, JH
    Moore, MAS
    BLOOD, 2002, 100 (11) : 34A - 34A
  • [48] Additional acquisition of t(1;21)(p32;q22) in a patient relapsing with acute myelogenous leukemia with NUP98-HOXA9
    Aoki, Takatoshi
    Miyamoto, Toshihiro
    Yoshida, Shuro
    Yamamoto, Asataro
    Yamauchi, Takuji
    Yoshimoto, Goichi
    Mori, Yasuo
    Kamezaki, Kenjiro
    Iwasaki, Hiromi
    Takenaka, Katsuto
    Harada, Naoki
    Nagafuji, Koji
    Teshima, Takanori
    Akashi, Koichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2008, 88 (05) : 571 - 574
  • [49] VARIATION IN HOXA9 EXPRESSION IN THE NUP98-HOXD13 MYELODYSPLASIA MODEL, USING A NOVEL HOXA9-EGFP REPORTER MOUSE
    Slape, Chris
    Zamora, Adriana Pliego
    Lisle, Jessica
    Huang, Johnny
    Zhao, Liang
    Koopman, Peter
    EXPERIMENTAL HEMATOLOGY, 2018, 64 : S104 - S104
  • [50] Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in AML
    Mohanty, Sagarajit
    Jyotsana, Nidhi
    Sharma, Amit
    Othman, Basem
    Kloos, Arnold
    Mandhania, Madhvi
    Schottmann, Renate
    Ramsay, Euan
    Vornlocher, Hans-Peter
    Ganser, Arnold
    Thol, Felicitas
    Heuser, Michael
    BLOOD, 2019, 134
12345